- Fresenius has confirmed its exit from investment company, Fresenius Vamed.
- The company has upgraded its revenue forecast for the financial year, from a previous +3% to +6%, to now seeing organic revenue growth of +4 to +7%.
- The estimated Ebit (Earnings before interest and taxes) also shows an increase, from previously +4% to +8%, now it is expected to be +6% to +10%.
- The improvement in group outlook is attributed to better business prospects for Fresenius Kabi.
- Fresenius Kabi now projects an organic revenue growth in mid to high single-digit percentage range for fiscal year 2024. This is an increase from the previous expectation of a mid single-digit percentage range.
- The Ebit margin for Fresenius Kabi is now anticipated to be between 15 and 16%, higher than the previous forecast of around 15%.
- The change of the group outlook also signifies that forecasts are now provided exclusing Fresenius Vamed.
- The firm now has 15 buys, 7 holds, and 0 sells in its business portfolio.
A look at Fresenius & KGaA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts at Smartkarma have provided an outlook for Fresenius SE & Co KGaA based on their Smart Scores. With a solid score in value and dividends, Fresenius is seen as a company with good financial health and potential for returns for investors. The company’s momentum score suggests a positive market sentiment, while growth and resilience scores indicate moderate performance in these areas. Fresenius, a global health care group offering various medical products and services, appears to have a promising long-term outlook according to these scores.
Similarly, for KGaA, the Smart Scores paint a picture of a company with strong value and dividend prospects, along with decent momentum in the market. Although growth and resilience scores are somewhat lower, overall, the outlook for KGaA is positive. As a global health care group providing dialysis, hospital, and medical care products and services, KGaA seems to be positioned well for the long term based on these Smart Scores.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
